Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Aging biology is a promising and burgeoning research area that can yield dual-purpose pathways and protein targets that may impact multiple diseases, while retarding or possibly even reversing age-associated processes. One widely used approach to classify a multiplicity of mechanisms driving the aging process is the hallmarks of aging. In addition to the classic nine hallmarks of aging, processes such as extracellular matrix stiffness, chronic inflammation and activation of retrotransposons are also often considered, given their strong association with aging. In this study, we used a variety of target identification and prioritization techniques offered by the AI-powered PandaOmics platform, to propose a list of promising novel aging-associated targets that may be used for drug discovery. We also propose a list of more classical targets that may be used for drug repurposing within each hallmark of aging. Most of the top targets generated by this comprehensive analysis play a role in inflammation and extracellular matrix stiffness, highlighting the relevance of these processes as therapeutic targets in aging and age-related diseases. Overall, our study reveals both high confidence and novel targets associated with multiple hallmarks of aging and demonstrates application of the PandaOmics platform to target discovery across multiple disease areas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982 · cited 4×
“These have been conceptualized in the hallmarks of aging composed of: Altered intercellular communications, Cellular senescence, Deregulated nutrient signaling, Epigenetic shift, Genomic instability, Impaired proteostasis, Mitochondrial dysfunction, Stem cell exhaustion, Telomere attrition [8].”
BackgroundInfluentialInflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690 · cited 1×
“Many of these targets play roles in inflammation, which is in line with the view that inflammation is associated with multiple agerelated diseases and is an intrinsic and major component of the aging processes [71].”
BackgroundInflammaging: a new immune–metabolic viewpoint for age-related diseases
Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0059-4 · Cited by 3,586 · cited 1×
“The hallmarks of aging have been widely used in the field as a starting point for studies, although they are not perfect, and arguably other mechanisms such as extracellular matrix stiffness [9], retrotranspositions [10] and inflammation [11] have also been reported to play an important role in aging.”
BackgroundHow to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“A substantial percentage of the human clinical trials, including those evaluating investigational anti-aging drugs, fail in Phase II, a phase where efficacy of the drug is tested [17, 18].”
BackgroundGeroscience: Linking Aging to Chronic Disease
Kennedy, B. K., Berger, S. L., Brunet, A., Campisi, J., Cuervo, A. M., Epel, E. S., Franceschi, C., Lithgow, G. J., Morimoto, R. I., Pessin, J. E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.039 · Cited by 2,764
Cellular senescence in aging and age-related disease: from mechanisms to therapy
Childs, B. G., Durik, M., Baker, D. J., & van Deursen, J. M. (2015) · Nature Medicine · doi:10.1038/nm.4000 · Cited by 2,363 · cited 1×
“For example, cellular senescence has been associated with pathologies such as cancer, type 2 diabetes, and atherosclerosis [12], as well as pulmonary, neurological, renal, hepatic, infectious, musculoskeletal, and endocrine diseases [13].”
BackgroundRapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287 · cited 1×
“Remarkedly, Food and Drug Administration (FDA)-approved mTOR inhibitor, rapamycin, was demonstrated to slow down aging and AADs in both preclinical settings and clinical trials [36, 37].”
BackgroundHuman Ageing Genomic Resources: new and updated databases
Tacutu, R., Thornton, D., Johnson, E., Budovsky, A., Barardo, D., Craig, T., Diana, E., Lehmann, G., Toren, D., Wang, J., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1042 · Cited by 738
Self-citationSirtuins in aging and age-related disease
Longo, V. D., & Kennedy, B. K. (2006) · Cell · doi:10.1016/j.cell.2006.07.002 · Cited by 628
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Strategies for targeting senescent cells in human disease
Gasek, N. S., Kuchel, G. A., Kirkland, J. L., & Xu, M. (2021) · Nature Aging · doi:10.1038/s43587-021-00121-8 · Cited by 501 · cited 2×
“For example, cellular senescence has been associated with pathologies such as cancer, type 2 diabetes, and atherosclerosis [12], as well as pulmonary, neurological, renal, hepatic, infectious, musculoskeletal, and endocrine diseases [13].”
BackgroundThe quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
The role of retrotransposable elements in ageing and age-associated diseases
Gorbunova, V., Seluanov, A., Mita, P., McKerrow, W., Fenyö, D., Boeke, J. D., Linker, S. B., Gage, F. H., Kreiling, J. A., Petrashen, A. P., et al. (2021) · Nature · doi:10.1038/s41586-021-03542-y · Cited by 446
Cross Talk among TGF- Signaling Pathways, Integrins, and the Extracellular Matrix
Munger, J. S., & Sheppard, D. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005017 · Cited by 372 · cited 11×
“Other than collagen, fibronectin is also a component of the ECM, where ITGAV:ITGB5 is one of the receptors for fibronectin.”
BackgroundInfluentialExtracellular matrix regulation of fibroblast function: redefining our perspective on skin aging
Cole, M. A., Quan, T., Voorhees, J. J., & Fisher, G. J. (2018) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-018-0459-1 · Cited by 365 · cited 1×
“Such fibroblasts synthesized fewer ECM proteins and more matrix-degrading metalloproteinases [80].”
BackgroundArtificial intelligence for aging and longevity research: Recent advances and perspectives
Zhavoronkov, A., Mamoshina, P., Vanhaelen, Q., Scheibye-Knudsen, M., Moskalev, A., & Aliper, A. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2018.11.003 · Cited by 246 · cited 2×
“Given the large number of datasets being generated, data-driven approaches (such as artificial intelligence [AI] and machine learning) are becoming instrumental across various fields in biology, including biomarker discovery and target prediction in aging [19].”
BackgroundBiohorology and biomarkers of aging: Current state-of-the-art, challenges and opportunities
Galkin, F., Mamoshina, P., Aliper, A., de Magalhães, J. P., Gladyshev, V. N., & Zhavoronkov, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101050 · Cited by 189
Self-citationHigh Levels of SIRT1 Expression as a Protective Mechanism Against Disease-Related Conditions
Elibol, B., & Kilic, U. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00614 · Cited by 171 · cited 1×
“The significance of the mTOR, the insulin/IGF, and the sirtuin pathways in longevity has been extensively reported, delineating their critical roles in counteracting multiple hallmarks of aging to delay the aging process or to extend lifespan [8, 34, 35].”
BackgroundTargeting aging mechanisms: pharmacological perspectives
Moskalev, A., Guvatova, Z., Lopes, I. D. A., Beckett, C. W., Kennedy, B. K., De Magalhaes, J. P., & Makarov, A. A. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.01.007 · Cited by 164 · cited 1×
“Research into longevity pharmacology has exploded in recent years with hundreds of compounds now known to extend lifespan in model organisms [3–7].”
BackgroundSelf-citationHDAC inhibitors: A new promising drug class in anti-aging research
Pasyukova, E. G., & Vaiserman, A. M. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.08.008 · Cited by 99
Age dependent increase in the levels of osteopontin inhibits skeletal muscle regeneration
Paliwal, P., Pishesha, N., Wijaya, D., & Conboy, I. M. (2012) · Aging · doi:10.18632/aging.100477 · Cited by 89 · cited 1×
“Neutralization of SPP1 recovered and enhanced the myogenic responses of old muscle stem cells, but failed to induce significant effect in young muscle stem cells, revealing the inhibitory effects of the age-dependent increase in SPP1 level on skeletal muscle regeneration [79].”
Background
Cited by
Biomarkers of aging for the identification and evaluation of longevity interventions
Moqri, M., Herzog, C., Poganik, J. R., Justice, J., Belsky, D. W., Higgins-Chen, A., Moskalev, A., Fuellen, G., Cohen, A. A., Bautmans, I., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.003 · Cited by 736
Self-citationRen, F., Ding, X., Zheng, M., Korzinkin, M., Cai, X., Zhu, W., Mantsyzov, A., Aliper, A., Aladinskiy, V., Cao, Z., et al. (2023) · Chemical Science · doi:10.1039/d2sc05709c · Cited by 365
Self-citationValidation of biomarkers of aging
Moqri, M., Herzog, C., Poganik, J. R., Ying, K., Justice, J. N., Belsky, D. W., Higgins-Chen, A. T., Chen, B. H., Cohen, A. A., Fuellen, G., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02784-9 · Cited by 361
Self-citationA small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models
Ren, F., Aliper, A., Chen, J., Zhao, H., Rao, S., Kuppe, C., Ozerov, I. V., Zhang, M., Witte, K., Kruse, C., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02143-0 · Cited by 348
“Given the scarcity of anti-fibrotic therapies for IPF or CKD, we used our published generative AI pipeline 14,15,40–42 to address this clinical need.”
InfluentialSelf-citationXu, Z., Ren, F., Wang, P., Cao, J., Tan, C., Ma, D., Zhao, L., Dai, J., Ding, Y., Fang, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03743-2 · Cited by 180
“As an answer to this question, our group used generative AI-driven discovery tools 22,23 to identify Traf2-and Nck-interacting kinase (TNIK) de novo as a critical regulator of idiopathic pulmonary fibrosis (IPF) pathology as it orchestrates multiple profibrotic and proinflammatory cellular programs…”
Self-citation
Metadata
- Authors
- Pun, F. W., Leung, G. H. D., Leung, H. W., Liu, B. H. M., Long, X., Ozerov, I. V., Wang, J., Ren, F., Aliper, A., Izumchenko, E., Moskalev, A., de Magalhães, J. P., & Zhavoronkov, A.
- Venue
- Aging
- Publisher
- Impact Journals, LLC
- Published
- 2022-03-29
- Volume
- 14
- Issue
- 6
- Pages
- 2475-2506
- ISSN
- 1945-4589 (ISSN-L)
- OpenAlex
- W4220717877
- Cited by
- 84
- References
- 21
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.